NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

體外診斷的全球市場:各產品種類、各手法、各用途、各終端用戶、各地區的預測 (2021年∼2028年)

Global In-Vitro Diagnostics Market - By Product Type, By Technique, By Application, and By End User and By Region - Global forecast from 2021-2028

出版商 SPER Market Research Pvt. Ltd. 商品編碼 1004278
出版日期 內容資訊 英文 218 Pages
商品交期: 最快1-2個工作天內
價格
體外診斷的全球市場:各產品種類、各手法、各用途、各終端用戶、各地區的預測 (2021年∼2028年) Global In-Vitro Diagnostics Market - By Product Type, By Technique, By Application, and By End User and By Region - Global forecast from 2021-2028
出版日期: 2021年04月01日內容資訊: 英文 218 Pages
簡介

全球體外診斷 (IVD)的市場規模,在預測期間內預計以3.8%的年複合成長率成長,至2028年達到1100億美元。隨著人們的生活方式的變化,疾病風險的預測和健康管理,慢性疾病管理等的需求高漲,成為市場的大促進因素。尤其是醫療標準未發展的國家和地區,有大幅市場成長空間。在各地區中,北美各國預計今後大幅度成長。

本報告提供全球體外診斷的市場相關分析,市場基本結構和主要的影響要素,整體市場規模趨勢預測,各產品種類、各手法、各用途、各終端用戶的市場佔有率結構,各地區的詳細趨勢,主要企業簡介等調查。

目錄

第1章 分析策略與市場趨勢

第2章 分析方法

第3章 摘要整理

第4章 市場洞察

  • 經濟要素分析
    • 促進因素
    • 市場趨勢
    • 市場機會
    • 課題
  • 市場參與企業與產品分析
  • 法律規範
  • 各企業的市場佔有率分析 (2020年)
  • 波特的五力分析
  • 新投資分析
  • PESTEL分析

第5章 全球體外診斷市場:概要

  • 市場規模與其預測 (2017年∼2028年)
    • 需求趨勢
  • 市場佔有率與其預測 (2017年∼2028年)
    • 各產品種類
    • 各手法
    • 各用途
    • 各終端用戶
    • 各地區

第6章 歐洲的體外診斷市場:概要

  • 市場規模與其預測 (2017年∼2028年)
  • 市場佔有率與其預測 (2017年∼2028年)
    • 各產品種類
    • 各手法
    • 各用途
    • 各終端用戶
    • 各國
    • 各企業市場佔有率 (前3名∼5名公司)
    • 對歐洲的體外診斷市場的經濟影響分析

第7章 北美的體外診斷市場:概要

第8章 亞太地區的體外診斷市場:概要

第9章 南美的體外診斷市場:概要

第10章 中東、非洲的體外診斷市場:概要

第11章 市場參與企業分析

  • 企業概要
  • 財務分析
  • 主要產品
  • 主要經營團隊
  • 聯絡原住所
  • SWOT分析
  • 企業簡介
目錄

The Global In-vitro Diagnostics market emerge the market growth owing to rising chronic diseases and development in advance technology

The global in-vitro diagnostics market size is projected to reach USD 110.0 billion by 2028 at a CAGR of 3.8% during the forecast period. With the changing lifestyle of people, there are higher requirements for disease risk prediction, health management, chronic disease management, etc. The In-vitro diagnostic market has vast room for development, especially in regions and countries with underdeveloped medical standards.

Among the types of IVD products, the localization rate of midstream products of molecular diagnosis is relatively high, and the downstream diagnosis service market is increasing. Also, information technology, big data, cloud computing, and the Internet have gradually strengthened interaction and integration with various industries and are also subverting the development model of multiple sectors.

Therefore, the traditional business model of the IVD industry is to obtain profits by selling instruments and reagent products, providing medical testing services and laboratory solutions, and the future development of the IVD industry will also usher in significant changes.

Product Overview in the Global In-vitro Diagnostics Market

Based on the product, the global In-Vitro Diagnostics market segmented into Reagents, Instruments, and Software & Services. The instrument segment has captured the highest market value in the comprehensive In-vitro diagnostics market in the forecast period from 2021-2028. It is mainly owing to the emerging need for early diagnosis of infectious diseases. Moreover, reagents will bolster the market demand for the global In-vitro diagnostics market. It is mainly owing to rising technology and convenient non-invasive device and home care kits.

Technique Overview in the Global In-vitro Diagnostics Market

Based on the technique, the global In-Vitro Diagnostics market classified into Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques. The Immunodiagnostics segment has dominated the market share of the global In-vitro diagnostics market. With the continuous development and progress of technology, the low-end immunodiagnosis field has achieved good localization results. However, the high-end immunodiagnosis field is still dominated by foreign giants and fuels the market demand for IVD in the future as well.

Application Overview in the Global In-vitro Diagnostics Market

Based on the application, the global In-Vitro Diagnostics market aggregated into Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications. Infectious diseases have the largest share in the in-vitro diagnostic market. It is mainly owing to the emerging conditions and outbreak of contagious diseases, causing epidemic fueled the market demand of IVD in the future as well.

End-use Overview in the Global In-vitro Diagnostics Market

Based on End-use, the global In-Vitro Diagnostics market classified into Standalone laboratories, Hospitals, Academic & Medical Schools, Point of Care Testing, and Others. The standalone laboratories have dominated the market share of the in-vitro diagnostic global market. It is mainly due to rising testing for new drugs, emerging viruses, and infectious diseases. Moreover, POCT will bolster its market demand in the future, owing to flexible and cost-effective medical devices that help in the diagnosis of conditions within a few minutes. Therefore, the market share of the global in-vitro diagnostics will fuel due to POCT rising demand.

Region Overview in the Global In-vitro Diagnostics Market

Based on geography, the global In-Vitro Diagnostics market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The North America region will be expecting to witness the highest growth during the forecast period from 2021-2028. It is Owing to rising disposable income, emerging technological advancement, adoption of non-invasive devices, and healthcare facilities.

Global In-vitro Diagnostics Market: Competitive Landscape

Companies such as

Abbott Laboratories

Becton

Dickinson and Company

bioMerieux SA

Bio-Rad Laboratories Inc.

Danaher Corporation (Beckman Coulter, Inc.)

      • F. Hoffmann-La Roche Ltd.

Johnson & Johnson

QIAGEN N.V.

Sysmex Corporation

Thermo Fisher Scientific Inc.

and others are key players in the global In-Vitro Diagnostics market.

Table of Contents

1. Research Strategic Development

  • 1.1. Market Modelling
  • 1.2. Product Analysis
  • 1.3. Market Trend and Economic Factors Analysis
  • 1.4. Market Segmental Analysis
  • 1.5. Geographical Mapping
  • 1.6. Country Wise Segregation

2. Research Methodology

  • 2.1. Identification of Target Market
  • 2.2. Data Acquisition
  • 2.3. Refining of Data/ Data Transformations
  • 2.4. Data Validation through Primary Techniques
  • 2.5. Exploratory Data Analysis
  • 2.6. Graphical Techniques/Analysis
  • 2.7. Quantitative Techniques/Analysis
  • 2.8. Visual Result/Presentation

3. Executive Summary

4. Market Insights

  • 4.1. Economic Factor Analysis
    • 4.1.1. Drivers
    • 4.1.2. Trends
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. Competitors & Product Analysis
  • 4.3. Regulatory Framework
  • 4.4. Company market share analysis, 2020
  • 4.5. Porter's Five forces analysis
  • 4.6. New Investment Analysis
  • 4.7. PESTEL Analysis

5. Global In-Vitro Diagnostics Market Overview

  • 5.1. Market Size & Forecast, 2017-2028
    • 5.1.1. Demand
      • 5.1.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast, 2017-2028
    • 5.2.1. By Product Type
      • 5.2.1.1. Reagents
      • 5.2.1.2. Instruments
      • 5.2.1.3. Software & Services
    • 5.2.2. By Technique
      • 5.2.2.1. Immunodiagnostics

5.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

5.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)

5.2.2.1.1.3. Fluorescence Immunoassays (FIAS)

5.2.2.1.1.4. Colorimetric Immunoassays (CIS)

      • 5.2.2.2. Rapid Tests
      • 5.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
      • 5.2.2.4. Radioimmunoassay
      • 5.2.2.5. Western Blot
      • 5.2.2.6. Hematology
      • 5.2.2.7. Molecular Diagnostics

5.2.2.7.1.1. Polymerase Chain Reaction (PCR)

5.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

5.2.2.7.1.3. Hybridization

5.2.2.7.1.4. DNA Diagnostics

5.2.2.7.1.5. Microarrays

5.2.2.7.1.6. Others

      • 5.2.2.8. Tissue Diagnostics
      • 5.2.2.9. Clinical Chemistry

5.2.2.9.1.1. Basic Metabolic Panel

5.2.2.9.1.2. Liver Panel

5.2.2.9.1.3. Lipid Profile

5.2.2.9.1.4. Thyroid Function Panel

5.2.2.9.1.5. Renal Profile

5.2.2.9.1.6. Electrolyte Panel

5.2.2.9.1.7. Specialty Chemicals

      • 5.2.2.10. Other IVD Techniques
    • 5.2.3. By Application
      • 5.2.3.1. Infectious Diseases
      • 5.2.3.2. Cancer
      • 5.2.3.3. Cardiac Diseases
      • 5.2.3.4. Immune System Disorders
      • 5.2.3.5. Nephrological Diseases
      • 5.2.3.6. Gastrointestinal Diseases
      • 5.2.3.7. Other Indications
    • 5.2.4. By End-user
      • 5.2.4.1. Standalone Laboratory
      • 5.2.4.2. Hospitals
      • 5.2.4.3. Academic & Medical Schools
      • 5.2.4.4. Point of Care Testing
      • 5.2.4.5. Others
    • 5.2.5. By Region
      • 5.2.5.1. Europe
      • 5.2.5.2. North America
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East & Africa

6. Europe In-Vitro Diagnostics Market Overview

  • 6.1. Europe In-Vitro Diagnostics Size & Forecast, 2017-2028
    • 6.1.1. Demand
      • 6.1.1.1. By Value (USD Million)
  • 6.2. Europe In-Vitro Diagnostics Market Share & Forecast, 2017-2028
    • 6.2.1. By Product Type
      • 6.2.1.1. Reagents
      • 6.2.1.2. Instruments
      • 6.2.1.3. Software & Services
    • 6.2.2. By Technique
      • 6.2.2.1. Immunodiagnostics

6.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

6.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)

6.2.2.1.1.3. Fluorescence Immunoassays (FIAS)

6.2.2.1.1.4. Colorimetric Immunoassays (CIS)

      • 6.2.2.2. Rapid Tests
      • 6.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
      • 6.2.2.4. Radioimmunoassay
      • 6.2.2.5. Western Blot
      • 6.2.2.6. Hematology
      • 6.2.2.7. Molecular Diagnostics

6.2.2.7.1.1. Polymerase Chain Reaction (PCR)

6.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

6.2.2.7.1.3. Hybridization

6.2.2.7.1.4. DNA Diagnostics

6.2.2.7.1.5. Microarrays

6.2.2.7.1.6. Others

      • 6.2.2.8. Tissue Diagnostics
      • 6.2.2.9. Clinical Chemistry

6.2.2.9.1.1. Basic Metabolic Panel

6.2.2.9.1.2. Liver Panel

6.2.2.9.1.3. Lipid Profile

6.2.2.9.1.4. Thyroid Function Panel

6.2.2.9.1.5. Renal Profile

6.2.2.9.1.6. Electrolyte Panel

6.2.2.9.1.7. Specialty Chemicals

      • 6.2.2.10. Other IVD Techniques
    • 6.2.3. By Application
      • 6.2.3.1. Infectious Diseases
      • 6.2.3.2. Cancer
      • 6.2.3.3. Cardiac Diseases
      • 6.2.3.4. Immune System Disorders
      • 6.2.3.5. Nephrological Diseases
      • 6.2.3.6. Gastrointestinal Diseases
      • 6.2.3.7. Other Indications
    • 6.2.4. By End-user
      • 6.2.4.1. Standalone Laboratory
      • 6.2.4.2. Hospitals
      • 6.2.4.3. Academic & Medical Schools
      • 6.2.4.4. Point of Care Testing
      • 6.2.4.5. Others
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.2. UK
      • 6.2.5.3. France
      • 6.2.5.4. Italy
      • 6.2.5.5. Rest of Europe
    • 6.2.6. Company Market Share (Top 3-5)
    • 6.2.7. Economic Impact Study on Europe In-Vitro Diagnostics Market

7. North America In-Vitro Diagnostics Market Overview

  • 7.1. North America In-Vitro Diagnostics Market Size & Forecast, 2017-2028
    • 7.1.1. Demand
      • 7.1.1.1. By Value (USD Million)
  • 7.2. North America In-Vitro Diagnostics Market Share & Forecast, 2017-2028
    • 7.2.1. By Product Type
      • 7.2.1.1. Reagents
      • 7.2.1.2. Instruments
      • 7.2.1.3. Software & Services
    • 7.2.2. By Technique
      • 7.2.2.1. Immunodiagnostics

7.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

7.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)

7.2.2.1.1.3. Fluorescence Immunoassays (FIAS)

7.2.2.1.1.4. Colorimetric Immunoassays (CIS)

      • 7.2.2.2. Rapid Tests
      • 7.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
      • 7.2.2.4. Radioimmunoassay
      • 7.2.2.5. Western Blot
      • 7.2.2.6. Hematology
      • 7.2.2.7. Molecular Diagnostics

7.2.2.7.1.1. Polymerase Chain Reaction (PCR)

7.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

7.2.2.7.1.3. Hybridization

7.2.2.7.1.4. DNA Diagnostics

7.2.2.7.1.5. Microarrays

7.2.2.7.1.6. Others

      • 7.2.2.8. Tissue Diagnostics
      • 7.2.2.9. Clinical Chemistry

7.2.2.9.1.1. Basic Metabolic Panel

7.2.2.9.1.2. Liver Panel

7.2.2.9.1.3. Lipid Profile

7.2.2.9.1.4. Thyroid Function Panel

7.2.2.9.1.5. Renal Profile

7.2.2.9.1.6. Electrolyte Panel

7.2.2.9.1.7. Specialty Chemicals

      • 7.2.2.10. Other IVD Techniques
    • 7.2.3. By Application
      • 7.2.3.1. Infectious Diseases
      • 7.2.3.2. Cancer
      • 7.2.3.3. Cardiac Diseases
      • 7.2.3.4. Immune System Disorders
      • 7.2.3.5. Nephrological Diseases
      • 7.2.3.6. Gastrointestinal Diseases
      • 7.2.3.7. Other Indications
    • 7.2.4. By End-user
      • 7.2.4.1. Standalone Laboratory
      • 7.2.4.2. Hospitals
      • 7.2.4.3. Academic & Medical Schools
      • 7.2.4.4. Point of Care Testing
      • 7.2.4.5. Others
    • 7.2.5. By Country
      • 7.2.5.1. US
      • 7.2.5.2. Canada
      • 7.2.5.3. Mexico
    • 7.2.6. Company Market Share (Top 3-5)
    • 7.2.7. Economic Impact Study on North America In-Vitro Diagnostics Market

8. Asia Pacific In-Vitro Diagnostics Overview

  • 8.1. Asia Pacific In-Vitro Diagnostics Market Size & Forecast, 2017-2028
    • 8.1.1. Demand
      • 8.1.1.1. By Value (USD Million)
  • 8.2. Asia Pacific In-Vitro Diagnostics Market Share & Forecast, 2017-2028
    • 8.2.1. By Product Type
      • 8.2.1.1. Reagents
      • 8.2.1.2. Instruments
      • 8.2.1.3. Software & Services
    • 8.2.2. By Technique
      • 8.2.2.1. Immunodiagnostics

8.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

8.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)

8.2.2.1.1.3. Fluorescence Immunoassays (FIAS)

8.2.2.1.1.4. Colorimetric Immunoassays (CIS)

      • 8.2.2.2. Rapid Tests
      • 8.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
      • 8.2.2.4. Radioimmunoassay
      • 8.2.2.5. Western Blot
      • 8.2.2.6. Hematology
      • 8.2.2.7. Molecular Diagnostics

8.2.2.7.1.1. Polymerase Chain Reaction (PCR)

8.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

8.2.2.7.1.3. Hybridization

8.2.2.7.1.4. DNA Diagnostics

8.2.2.7.1.5. Microarrays

8.2.2.7.1.6. Others

      • 8.2.2.8. Tissue Diagnostics
      • 8.2.2.9. Clinical Chemistry

8.2.2.9.1.1. Basic Metabolic Panel

8.2.2.9.1.2. Liver Panel

8.2.2.9.1.3. Lipid Profile

8.2.2.9.1.4. Thyroid Function Panel

8.2.2.9.1.5. Renal Profile

8.2.2.9.1.6. Electrolyte Panel

8.2.2.9.1.7. Specialty Chemicals

      • 8.2.2.10. Other IVD Techniques
    • 8.2.3. By Application
      • 8.2.3.1. Infectious Diseases
      • 8.2.3.2. Cancer
      • 8.2.3.3. Cardiac Diseases
      • 8.2.3.4. Immune System Disorders
      • 8.2.3.5. Nephrological Diseases
      • 8.2.3.6. Gastrointestinal Diseases
      • 8.2.3.7. Other Indications
    • 8.2.4. By End-user
      • 8.2.4.1. Standalone Laboratory
      • 8.2.4.2. Hospitals
      • 8.2.4.3. Academic & Medical Schools
      • 8.2.4.4. Point of Care Testing
      • 8.2.4.5. Others
    • 8.2.5. By Country
      • 8.2.5.1. China
      • 8.2.5.2. India
      • 8.2.5.3. Japan
      • 8.2.5.4. Australia
      • 8.2.5.5. Rest of Asia Pacific
    • 8.2.6. Company Market Share (Top 3-5)
    • 8.2.7. Economic Impact Study on Asia Pacific In-Vitro Diagnostics Market

9. South America In-Vitro Diagnostics Market Overview

  • 9.1. South America In-Vitro Diagnostics Market Size & Forecast, 2017-2028
    • 9.1.1. Demand
      • 9.1.1.1. By Value (USD Million)
  • 9.2. South America In-Vitro Diagnostics Market Share & Forecast, 2017-2028
    • 9.2.1. By Product Type
      • 9.2.1.1. Reagents
      • 9.2.1.2. Instruments
      • 9.2.1.3. Software & Services
    • 9.2.2. By Technique
      • 9.2.2.1. Immunodiagnostics

9.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

9.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)

9.2.2.1.1.3. Fluorescence Immunoassays (FIAS)

9.2.2.1.1.4. Colorimetric Immunoassays (CIS)

      • 9.2.2.2. Rapid Tests
      • 9.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
      • 9.2.2.4. Radioimmunoassay
      • 9.2.2.5. Western Blot
      • 9.2.2.6. Hematology
      • 9.2.2.7. Molecular Diagnostics

9.2.2.7.1.1. Polymerase Chain Reaction (PCR)

9.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

9.2.2.7.1.3. Hybridization

9.2.2.7.1.4. DNA Diagnostics

9.2.2.7.1.5. Microarrays

9.2.2.7.1.6. Others

      • 9.2.2.8. Tissue Diagnostics
      • 9.2.2.9. Clinical Chemistry

9.2.2.9.1.1. Basic Metabolic Panel

9.2.2.9.1.2. Liver Panel

9.2.2.9.1.3. Lipid Profile

9.2.2.9.1.4. Thyroid Function Panel

9.2.2.9.1.5. Renal Profile

9.2.2.9.1.6. Electrolyte Panel

9.2.2.9.1.7. Specialty Chemicals

      • 9.2.2.10. Other IVD Techniques
    • 9.2.3. By Application
      • 9.2.3.1. Infectious Diseases
      • 9.2.3.2. Cancer
      • 9.2.3.3. Cardiac Diseases
      • 9.2.3.4. Immune System Disorders
      • 9.2.3.5. Nephrological Diseases
      • 9.2.3.6. Gastrointestinal Diseases
      • 9.2.3.7. Other Indications
    • 9.2.4. By End-user
      • 9.2.4.1. Standalone Laboratory
      • 9.2.4.2. Hospitals
      • 9.2.4.3. Academic & Medical Schools
      • 9.2.4.4. Point of Care Testing
      • 9.2.4.5. Others
    • 9.2.5. By Country
      • 9.2.5.1. Brazil
      • 9.2.5.2. Argentina
      • 9.2.5.3. Rest of South America
    • 9.2.6. Company Market Share (Top 3-5)
    • 9.2.7. Economic Impact Study on South America In-Vitro Diagnostics Market

10. Middle East & Africa In-Vitro Diagnostics Market Overview

  • 10.1. Middle East & Africa In-Vitro Diagnostics Market Size & Forecast, 2017-2028
    • 10.1.1. Demand
      • 10.1.1.1. By Value (USD Million)
  • 10.2. Middle East & Africa In-Vitro Diagnostics Market Share & Forecast, 2018-2028
    • 10.2.1. By Product Type
      • 10.2.1.1. Reagents
      • 10.2.1.2. Instruments
      • 10.2.1.3. Software & Services
    • 10.2.2. By Technique
      • 10.2.2.1. Immunodiagnostics

10.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

10.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)

10.2.2.1.1.3. Fluorescence Immunoassays (FIAS)

10.2.2.1.1.4. Colorimetric Immunoassays (CIS)

      • 10.2.2.2. Rapid Tests
      • 10.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
      • 10.2.2.4. Radioimmunoassay
      • 10.2.2.5. Western Blot
      • 10.2.2.6. Hematology
      • 10.2.2.7. Molecular Diagnostics

10.2.2.7.1.1. Polymerase Chain Reaction (PCR)

10.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

10.2.2.7.1.3. Hybridization

10.2.2.7.1.4. DNA Diagnostics

10.2.2.7.1.5. Microarrays

10.2.2.7.1.6. Others

      • 10.2.2.8. Tissue Diagnostics
      • 10.2.2.9. Clinical Chemistry

10.2.2.9.1.1. Basic Metabolic Panel

10.2.2.9.1.2. Liver Panel

10.2.2.9.1.3. Lipid Profile

10.2.2.9.1.4. Thyroid Function Panel

10.2.2.9.1.5. Renal Profile

10.2.2.9.1.6. Electrolyte Panel

10.2.2.9.1.7. Specialty Chemicals

      • 10.2.2.10. Other IVD Techniques
    • 10.2.3. By Application
      • 10.2.3.1. Infectious Diseases
      • 10.2.3.2. Cancer
      • 10.2.3.3. Cardiac Diseases
      • 10.2.3.4. Immune System Disorders
      • 10.2.3.5. Nephrological Diseases
      • 10.2.3.6. Gastrointestinal Diseases
      • 10.2.3.7. Other Indications
    • 10.2.4. By End-user
      • 10.2.4.1. Standalone Laboratory
      • 10.2.4.2. Hospitals
      • 10.2.4.3. Academic & Medical Schools
      • 10.2.4.4. Point of Care Testing
      • 10.2.4.5. Others
    • 10.2.5. By Country
      • 10.2.5.1. Saudi Arabia
      • 10.2.5.2. UAE
      • 10.2.5.3. South Africa
      • 10.2.5.4. Rest of Middle East & Africa
    • 10.2.6. Company Market Share (Top 3-5)
    • 10.2.7. Economic Impact Study on Middle East & Africa In-Vitro Diagnostics Market

11. Competitor Analysis

  • 11.1. Company Description
  • 11.2. Financial Analysis
  • 11.3. Key Products
  • 11.4. Key Management Personnel
  • 11.5. Contact Address
  • 11.6. SWOT Analysis
  • 11.7. Company Profile
      • 11.7.1.1. Abbott Laboratories
      • 11.7.1.2. Becton, Dickinson and Company
      • 11.7.1.3. bioMerieux SA
      • 11.7.1.4. Bio-Rad Laboratories, Inc.
      • 11.7.1.5. Danaher Corporation (Beckman Coulter, Inc.)
      • 11.7.1.6. F. Hoffmann-La Roche Ltd.
      • 11.7.1.7. Johnson & Johnson
      • 11.7.1.8. QIAGEN N.V.
      • 11.7.1.9. Sysmex Corporation
      • 11.7.1.10. Thermo Fisher Scientific, Inc
      • 11.7.1.11. Other players